linjc16/ctgov huggingface dataset:
The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
Liver transplantation has become the accepted treatment option for advanced liver failure in recent years. In addition to the increase in the number of centers performing transplant and the decrease in complication rates depending on the experience gained, the most common biliary complications did not improve at the desired level. For this reason, studies in this field are frequent today. The structural complexities of HLA antigens have been the subject of investigation in recent years. With the development of DNA and RNA amplification methods; It is increasingly difficult for physicians to keep up with the increasing burden of knowledge regarding the genetic aspects of these antigens. Concrete benefits of this gene complex, which has been investigated in various fields and preserves its mystery, have not been determined in liver transplant patients. However, there are publications showing its connection with the bile epithelium in liver transplantation and its relationship with the disappearing bile duct syndrome. In this study, our aim is to explain whether the bile duct complications, which appear like a continuous wall and can lead to frightening pictures, are related to HLA tissue compatibility.

Official Title
-----------------
The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

Conditions
-----------------
Liver Transplant; Complications, HLA Antigens

Intervention / Treatment
-----------------
* Other: HLA antigen results


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with liver transplantation and tested for HLA antigen (recipient - donor) Exclusion Criteria: patients who died early Patients whose HLA antigen is not checked

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with biliary complications<br>patients with postoperative biliary fistula, biliary stenosis | Other: HLA antigen results<br>* HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.<br>|
| Patients without biliary complications<br>patients without postoperative biliary fistula and biliary stenosis | Other: HLA antigen results<br>* HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bliary complications | Biliary fistüla, biliary stenosis | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver Transplant, Complications, HLA, biliary fistula, biliary stricture
Prevalence of Thrombosis in COVID-Patients

Study Overview
=================
Brief Summary
-----------------
Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status. Assessment of health issues and cognitive function as late complication after infection.

Official Title
-----------------
Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: duplex sonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SARS CoV 2 positive swap, at least 4 weeks after infection Exclusion Criteria: under 18 years old no consent anemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID 19 patients<br>all patients with positive SARS-CoV 2 swap | Diagnostic Test: duplex sonography<br>* all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling<br>* Other names: blood sample;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of thrombosis |  | 20 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation to immunity |  | 20 minutes | 
| Assessment of late complications |  | 20 minutes |
Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine soluble HJV could be an early diagnosis urinary biomarker of ischemia/reperfusion injury in post CPB-patients.

Detailed Description
-----------------
Acute kidney injury (AKI) is a common syndrome on Intensive Care Unit, and renal dysfunction would result in a further morbidity and mortality. Critical ills complicated with acute kidney injury are usually accompanied with multi-organ failure. Therefore, National Taiwan University Hospital Study group of Acute Renal Failure (NSARF) realizes that the characteristics of AKI is resulted from the perfusion less of body fluid and attempt to develop therapies to prevent or attenuate AKI, which have had limited success. We attempt to use the novel biomarker soluble hemojuvelin (sHJV) to evaluate the iron homeostasis on acute kidney injury and develop new strategies and therapies such as protease inhibitors on kidney function, as safety markers to monitor toxicity and as measures of treatment effect. Besides, we will focus on validation the sensitivity and specificity of sHJV on the clinical specimen of post-operative patients from NSARF data-bank. Merge the renal function and other types of biomarkers as panel to predict the post-operative outcome. Based on the different expression of these markers, using a panel of serum and urine markers may potentially help us to distinguish between various types of insults, establish the duration and severity of injury, predict the clinical outcome and help to monitor response to treatment in AKI.

Official Title
-----------------
Early Diagnosis of Postoperative Acute Renal Failure - Using Biomarker to Predict the Outcome of Cardiac Surgery Associated Acute Kidney Injury

Conditions
-----------------
Acute Renal Failure, Acute Kidney Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AKI is defined as a serum creatinine level greater that 50% more than baseline during the first 3 postoperative days (PODs), and non-AKI, as a less than 10% increase. Exclusion Criteria: Patients with chronic kidney disease (baseline estimated glomerular filtration rate < 60 mL/min/1.73 m2 as calculated by using the 4-variable Modification of Diet in Renal Disease Study equation, or protein-creatinine ratio > 100 mg/mmol) are excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proteinuria predict outcome, BNP and NGAL predict outcome, Pre-operative GFR and proteinuria
Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

Study Overview
=================
Brief Summary
-----------------
The purpose of the current study is to demonstrate non-inferiority of everolimus-eluting bioresorbable vascular scaffold to everolimus-eluting stents in patients with chronic total occlusion regarding the antirestenotic efficacy at 8 to 10-month angiographic follow-up.

Official Title
-----------------
Everolimus-eluting Bioresorbable Vascular Scaffolds Versus Everolimus-eluting Stents in Patients With Chronic Total Occlusion

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Everolimus-eluting bioresorbable vascular scaffold
* Device: Everolimus-eluting stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical inclusion criteria: Age ≥18 years Angina pectoris, equivalent symptoms, and/or positive stress test Viable myocardium subtended by chronic total occlusion Negative pregnancy test in women with childbearing potential Angiographic inclusion criteria: Chronic total occlusion defined as Thrombolysis in Myocardial Infarction flow 0 with an estimated duration ≥3 months Successful wire passage and assumption of successful stent/scaffold deployment Target reference vessel diameter 2.5 - 4.0 mm Exclusion Criteria: Clinical exclusion criteria: Limited long-term prognosis with a life-expectancy <12 months Contraindications to antiplatelet therapy Known allergy against cobalt chrome, everolimus, or polylactic acid Angiographic exclusion criteria: Target lesion located in the left main trunk Target lesion located in a coronary bypass graft Bifurcation lesion with planned two-stent strategy Indication for coronary artery bypass grafting

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bioresorbable vascular scaffold<br>Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion | Device: Everolimus-eluting bioresorbable vascular scaffold<br>* Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion<br>|
| Active Comparator: Stent<br>Implantation everolimus-eluting stent in chronic total occlusion | Device: Everolimus-eluting stent<br>* Implantation of everolimus-eluting stent in chronic total occlusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-stent late lumen loss assessed by angiography |  | 8-10 months after the index procedure |
A Real-world Study of Albumin-bound Paclitaxel in the Treatment of Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
Pancreatic cancer progresses rapidly and has a higher death rate. Albumin-bound paclitaxel is a new generation of paclitaxel . Albumin-bound paclitaxel is recommended as a class 1A evidence treating patients with pancreatic cancer.The purpose of this study was to further observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel in the treatment of non-operative locally advanced or metastatic pancreatic cancer and to explore the prognostic factors .

Detailed Description
-----------------
This is a prospective, single-arm, observational study. After the subjects meet the inclusive and exclusive criteria, then they will receive albumin-bound paclitaxel treatment. The researchers can choose the treatment based on albumin-bound paclitaxel and choose dosage according to the patient's condition.

Official Title
-----------------
A Real-world Study of on Albumin-bound Paclitaxel as First-line Treatment of Patients With Non-operative Locally Advanced or Metastatic Pancreatic Cancer

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18 -80, male or female; Non-operative patients with locally advanced or metastatic pancreatic cancer diagnosed by pathology or histology (except islet cell carcinoma); The patient has not received standard systematic treatment in the past, and the metastatic site has not received any local treatment, including radiotherapy, chemotherapy, surgical treatment, etc.; At least one measurable lesion (CT scan length of tumor lesion is greater than 10 mm, CT scan short diameter of lymph node lesion is greater than 15 mm, scanning layer thickness is not greater than 5 mm); The subjects volunteered to participate in this study and signed the informed consent form, with good compliance to follow-up. Exclusion Criteria: Pregnant or lactating women; Patients allergy to albumin-bound paclitaxel or its excipients Patients with albumin-bound paclitaxel contraindication; Doctors consider those who are not suitable for this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival | the date from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first. | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pancreatic cancer, albumin-bound paclitaxel
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome

Study Overview
=================
Brief Summary
-----------------
To determine the phenotype of patients having PMR symptoms and primary Sjogren syndrome (pSS), we used a French national call to identify patients combining both diseases and collected retrospective clinical and biological data.

Detailed Description
-----------------
A national call to identify patients combining pSS and PMR was disseminated in France. Patients with Sjögren's syndrome associated with rheumatoid arthritis were excluded. We described the global population having both diseases and compared them to two historic prospective cohorts of isolated pSS (the prospective cohort of primary Sjögren DiapSS), or isolated PMR (TENOR, a cohort of recent PMR), regarding clinical, imaging and treatments characteristics.

Official Title
-----------------
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome : A French Multicentric Retrospective Study (PASS)

Conditions
-----------------
Polymyalgia Rheumatica, Sjogren's Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fulfilling the ACR/EULAR 2012 criteria for PMR and the ACR/EULAR 2016 criteria for pSS Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical data | pain (pain scale) | at diagnosis | 
| biological data | biology (CRP in mg/L) | at diagnosis | 
| biological data | presence of anti-SSA/SSB (yes/no) | at diagnosis | 
| histological data | accesories salivary glands biopsies (focus score) | at diagnosis | 
| imaging data | US (presence of shoulder involvement yes/no; hip involvement yes/no) | at diagnosis | 
| treatments data | use of methotrexate yes/no; abatacept yes/no, rituximab yes/no, corticosteroids yes/no; pilocarpine yes/no; hydroxychloroquine yes/no | at inclusion ( day 0) |
Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough

Study Overview
=================
Brief Summary
-----------------
This study seeks to subjectively evaluate whether a single application of Vicks® VapoRub® (VVR) ointment or a control ointment (petrolatum) will be superior to no treatment for control of nocturnal cough and congestion due to upper respiratory tract infection (URI) as rated by both parents and children.

Official Title
-----------------
Effect of a Medicated Topical Therapy, Petrolatum, and No Treatment on Nocturnal Cough and Congestion for Children With Upper Respiratory Infections

Conditions
-----------------
Respiratory Tract Diseases

Intervention / Treatment
-----------------
* Other: Ointment containing camphor, eucalyptus oil, and menthol
* Other: Petroleum jelly


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cough and congestion attributed to upper respiratory tract infection Exclusion Criteria: Children with signs or symptoms of more serious or treatable disease Presence of itchy, watery eyes or frequent sneezing Tachypnea (respiratory rate >95%ile) or labored breathing Symptoms for 8 or more days History of asthma in the past 2 years, chronic lung disease, or seizure disorder History of an allergic reaction to camphor, menthol, eucalyptus, petrolatum, cedarleaf oil, nutmeg oil, thymol, turpentine oil, Over-the-counter medication containing VVR components

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br> | Other: Ointment containing camphor, eucalyptus oil, and menthol<br>* One time use<br>|
| Placebo Comparator: B<br> | Other: Petroleum jelly<br>* One time use<br>|
| No Intervention: 3<br>no intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective assessment of cough and congestion symptoms |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cough symptoms, Cold symptoms, Congestion, Children, URI, Alternative cough symptom treatment
Nutrient Fortified Oat Drink

Study Overview
=================
Brief Summary
-----------------
This study will follow a randomized, double-blind, placebo-controlled, parallel-group design to test if an oat beverage fortified with iron, zinc vitamin A and vitamin C will improve nutrient status and iron deficiency in young children compared to an unfortified control beverage.

Official Title
-----------------
The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children

Conditions
-----------------
Iron Deficiency Anemia

Intervention / Treatment
-----------------
* Other: Dietary Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 5-7 years old Children with parental consent Not suffering from diarrhea, respiratory infections and fever at time of interview and for the past two weeks No history of blood disorder or malaria Had not participated in any feeding program for the past 4 months Children with Hb > 70 g/L to <120 g/L (WHO/UNICEF/UNU, 1998) CRP <10 mg/L Exclusion Criteria: All children aged < 5 years old and > 7 years old Without parental consent Undergoing treatment for any chronic ailment, diagnosed as suffering from any sort of illness e.g. fever, diarrhea, stomach ache, cough and colds at the time of examination or during the past two weeks. Reported current or history of blood abnormalities/hemoglobinopathies Children with all normal Hb levels or very low Hb < 70 g/L CRP >10mg/L

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nutrient Fortified Beverage<br> | Other: Dietary Intervention<br>* Nutrient fortified oat beverage<br>|
| Placebo Comparator: Control<br> | Other: Dietary Intervention<br>* Nutrient fortified oat beverage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Iron status: Change in hemoglobin and serum ferritin |  | Baseline and 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| zinc, vitamin A and vitamin C status |  | Baseline and 4 months | 
| Weight, height, CRP and frequency of illness |  | Baseline and 4 months | 
| Dietary intake |  | Baseline and 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iron deficiency anemia, iron, zinc, vitamin A, vitamin C, oats